The combination of metformin and a dipeptidyl peptidase IV inhibitor prevents 5-fluorouracil-induced reduction of small intestine weight

European Journal of Pharmacology

Volumn 488, Issue 1-3, 2004, Pages 213-218

  Yamazaki, Kazuto ^a   Yasuda, Nobuyuki ^a   Inoue, Takashi ^a   Nagakura, Tadashi ^a   Kira, Kazunobu ^a   Saeki, Takao ^a   Tanaka, Isao ^a  

^a EISAI CO LTD   (Japan)

Author keywords

Biguanide; Dipeptidyl peptidase IV; Glucagon like peptide 2; Intestine

Indexed keywords

BIGUANIDE DERIVATIVE; BUFORMIN; DIBETOS B; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; ENZYME INHIBITOR; FLUOROURACIL; GLUCAGON LIKE PEPTIDE 2; METFORMIN; PHENFORMIN; UNCLASSIFIED DRUG; VALINE PYRROLIDIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; DIGESTIVE SYSTEM INJURY; DRUG EFFECT; FEMALE; HORMONE BLOOD LEVEL; HORMONE RELEASE; MALE; MOUSE; NONHUMAN; ORGAN WEIGHT; PRIORITY JOURNAL; RAT; SMALL INTESTINE; WEIGHT REDUCTION;

ANIMALS; ANTIGENS, CD26; ANTIMETABOLITES; BIGUANIDES; ENTEROENDOCRINE CELLS; FLUOROURACIL; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDE 2; HYPOGLYCEMIC AGENTS; INTESTINE, SMALL; MALE; METFORMIN; MICE; MICE, INBRED BALB C; ORGAN SIZE; PEPTIDES; PROTEASE INHIBITORS; PYRROLES; RATS; RATS, INBRED F344; VALINE;

EID: 1642384373     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2004.02.019     Document Type: Article

References (34)

1. Ahrén B., Holst J.J., Mårtensson H., Balkan B. Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice. Eur. J. Pharmacol. 404:2000;239-245.
2. Batterham R.L., Bloom S.R. The gut hormone peptide YY regulates appetite. Ann. N.Y. Acad. Sci. 994:2003;162-168.
3. Boushey R.P., Yusta B., Drucker D.J. Glucagon-like peptide 2 decreases mortality and reduces the severity of indomethacin-induced murine enteritis. Am. J. Physiol. 277:1999;E937-E947.
4. Boushey R.P., Yusta B., Drucker D.J. Glucagon-like peptide (GLP)-2 reduces chemotherapy-associated mortality and enhances cell survival in cells expressing a transfected GLP-2 receptor. Cancer Res. 61:2001;687-693.
5. Burrin D.G., Stoll B., Guan X. Glucagon-like peptide 2 function in domestic animals. Domest. Anim. Endocrinol. 24:2003;103-122.
6. Chance W.T., Zhang X., Balasubramaniam A., Fischer J.E. Preservation of intestine protein by peptide YY during total parenteral nutrition. Life Sci. 58:1996;1785-1794.
7. Chance W.T., Foley-Nelson T., Thomas I., Balasubramaniam A. Prevention of parenteral nutrition-induced gut hypoplasia by coinfusion of glucagon-like peptide-2. Am. J. Physiol. 273:1997;G559-G563.
8. Chance W.T., Sheriff S., Foley-Nelson T., Thomas I., Balasubramaniam A. Maintaining gut integrity during parenteral nutrition of tumor-bearing rats: effects of glucagon-like peptide 2. Nutr. Cancer. 37:2000;215-222.
9. Drucker D.J. Glucagon-like peptides. Diabetes. 47:1998;159-169.
10. Drucker D.J. Glucagon-like peptide 2. Trends Endocrinol. Metab. 10:1999;153-156.
11. Drucker D.J. Biological actions and therapeutic potential of the glucagon-like peptides. Gastroenterology. 122:2002;531-544.
12. Drucker D.J. Gut adaptation and the glucagon-like peptides. Gut. 50:2002;428-435.
13. Drucker D.J., Yusta B., Boushey R.P., DeForest L., Brubaker P.L. Human [Gly2]GLP-2 reduces the severity of colonic injury in a murine model of experimental colitis. Am. J. Physiol. 276:1999;G79-G91.
14. Gomez G., Zhang T., Rajaraman S., Thakore K.N., Yanaihara N., Townsend C.M. Jr., Thompson J.C., Greeley G.H. Intestinal peptide YY: ontogeny of gene expression in rat bowel and trophic actions on rat and mouse bowel. Am. J. Physiol. 268:1995;G71-G81.
15. Goodlad R.A., Lenton W., Ghatei M.A., Adrian T.E., Bloom S.R., Wright N.A. Effects of an elemental diet, inert bulk and different types of dietary fibre on the response of the intestinal epithelium to refeeding in the rat and relationship to plasma gastrin, enteroglucagon, and PYY concentrations. Gut. 28:1987;171-180.
16. Hansen L., Hartmann B., Bisgaard T., Mineo H., Jørgensen P.N., Holst J.J. Somatostatin restrains the secretion of glucagon-like peptide-1 and -2 from isolated perfused porcine ileum. Am. J. Physiol. Endocrinol. Metab. 278:2000;E1010-E1018.
17. Hartmann B., Ørskov C., Wettergren A., Holst J.J. Diurnal profiles of glucagon-like peptides 1 and 2 (GLP-1 and GLP-2) in normal man. Diabetologia. 38(Suppl. 1):1995;A167.
18. Hartmann B., Thulesen J., Kissow H., Thulesen S., Orskov C., Ropke C., Poulsen S.S., Holst J.J. Dipeptidyl peptidase IV inhibition enhances the intestinotrophic effect of glucagon-like peptide-2 in rats and mice. Endocrinology. 141:2000;4013-4020.
19. 1 analog, OP-1206, alleviates 5-fluorouracil-induced injury of rat small intestine. Res. Commun. Mol. Pathol. Pharmacol. 104:1999;243-251.
20. Jeppesen P.B., Hartmann B., Thulesen J., Graff J., Lohmann J., Hansen B.S., Tofteng F., Poulsen S.S., Madsen J.L., Holst J.J., Mortensen P.B. Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon. Gastroenterology. 120:2001;806-815.
21. Kouris G.J., Liu Q., Rossi H., Djuricin G., Gattuso P., Nathan C., Weinstein R.A., Prinz R.A. The effect of glucagon-like peptide 2 on intestinal permeability and bacterial translocation in acute necrotizing pancreatitis. Am. J. Surg. 181:2001;571-575.
22. Ljungmann K., Hartmann B., Kissmeyer-Nielsen P., Flyvbjerg A., Holst J.J., Laurberg S. Time-dependent intestinal adaptation and GLP-2 alterations after small bowel resection in rats. Am. J. Physiol.: Gastrointest. Liver Physiol. 281:2001;G779-G785.
23. Ørskov C., Holst J.J., Knuhtsen S., Baldissera F.G., Poulsen S.S., Nielsen O.V. Glucagon-like peptides GLP-1 and GLP-2, predicted products of the glucagon gene, are secreted separately from pig small intestine but not pancreas. Endocrinology. 119:1986;1467-1475.
24. Prasad R., Alavi K., Schwartz M.Z. Glucagonlike peptide-2 analogue enhances intestinal mucosal mass after ischemia and reperfusion. J. Pediatr. Surg. 35:2000;357-359.
25. Roberge J.N., Gronau K.A., Brubaker P.L. Gastrin-releasing peptide is a novel mediator of proximal nutrient-induced proglucagon-derived peptide secretion from the distal gut. Endocrinology. 137:1996;2383-2388.
26. Rocca A.S., Brubaker P.L. Role of the vagus nerve in mediating proximal nutrient-induced glucagon-like peptide-1 secretion. Endocrinology. 140:1999;1687-1694.
27. Scott R.B., Kirk D., MacNaughton W.K., Meddings J.B. GLP-2 augments the adaptive response to massive intestinal resection in rat. Am. J. Physiol. 275:1998;G911-G921.
28. Sigalet D.L. ALX-0600 (NPS Allelix). Curr. Opin. Investig. Drugs. 2:2001;505-509.
29. Tamaki T., Naomoto Y., Kimura S., Kawashima R., Shirakawa Y., Shigemitsu K., Yamatsuji T., Haisa M., Gunduz M., Tanaka N. Apoptosis in normal tissues induced by anti-cancer drugs. J. Int. Med. Res. 31:2003;6-16.
30. Tavakkolizadeh A., Shen R., Abraham P., Kormi N., Seifert P., Edelman E.R., Jacobs D.O., Zinner M.J., Ashley S.W., Whang E.E. Glucagon-like peptide 2: a new treatment for chemotherapy-induced enteritis. J. Surg. Res. 91:2000;77-82.
31. Tsai C.H., Hill M., Asa S.L., Brubaker P.L., Drucker D.J. Intestinal growth-promoting properties of glucagon-like peptide-2 in mice. Am. J. Physiol. 273:1997;E77-E84.
32. Varndell I.M., Bishop A.E., Sikri K.L., Uttenthal L.O., Bloom S.R., Polak J.M. Localization of glucagon-like peptide (GLP) immunoreactants in human gut and pancreas using light and electron microscopic immunocytochemistry. J. Histochem. Cytochem. 33:1985;1080-1086.
33. Voisin T., Bens M., Cluzeaud F., Vandewalle A., Laburthe M. Peptide YY receptors in the proximal tubule PKSV-PCT cell line derived from transgenic mice. Relation with cell growth. J. Biol. Chem. 268:1993;20547-20554.
34. Yasuda N., Inoue T., Nagakura T., Yamazaki K., Kira K., Saeki T., Tanaka I. Enhanced secretion of glucagon-like peptide 1 by biguanide compounds. Biochem. Biophys. Res. Commun. 298:2002;779-784.